Jn Biosciences LLC

Pdl Biopharma, Inc.

The University of Texas System

Eli Lilly and Company

Progenics Pharmaceuticals, Inc.

Facet Biotech Corporation

Gene Techno Science Co., Ltd.

Washington University

National Cheng-Kung University

Kaken Pharmaceutical Company, Ltd.

Abbott Biotherapeutics Corp.

Genetics Institute, Inc.

Abbvie Biotherapeutics Inc.

Protein Design Labs, Inc.

Cellerant Therapeutics, Inc.

Naoya Tsurushita

J Yun Tso

Shankar Kumar

Paul Robert Hinton

Maximiliano Vasquez

Yong-Jun Liu

Kui Shin Voo

Laura Bover

Nicholas F Landolfi

William C Olson

Koji Nakamura

Paul J Maddon

Steven Marc Paul

David Michael Holtzman

Toru Kanke

Kelly R Bales

Ronald DeMattos

Ming-Shi Chang

Cary L Queen

Kentaro Okamura

Shigeyuki Kon

Leonard G Presta

Jagath Reddy Junutula

Clive R Wood

Mary Collins

Gary S Gray

Dangshe Ma

Martin R Jefson

Beatriz M Carreno

Katherine Jane Turner

Denise M O'Hara

Ying-Ping Jiang

Toshimitsu Uede

Ronald Bradley Demattos

Hiroyuki Yanai

Omar Duramad

Maki Tamura

Yoshiko Akamatsu

Tsuneaki Asai

Maximillano Vasquez

Gerald P Donovan

Michael K Ahlijanian

Tatsuhiro Harada

Albert Cupo

Rie Tajima

Andre J Marozsan

Balaji Balasa

Donna Morris

Kirsten Nagashima

Brian Kennedy

Yun Kang

Maximilano Vasquez

Nicolas F Landolfi

David M Holtzman

Steven M Paul

Yun J Tso

The invention provides bifunctional molecules including an antibody specifically binding to CD122 and an extracellular domain of CTLA-4. The bifunctional molecules specifically bind to CD122 and CTLA-4 ligands, CD80 and CD86 and inhibit their function in immune activation. The bifunctional molecules can inhibit interaction of CD122 with its ligands IL-2 and IL-15 and inhibit interaction of CD80 and CD86 with their counter-receptor, CD28. These bifunctional molecules can suppress Signals 2 and 3 of immune responses as a single therapeutic agent for treatment of immune disorders.

Bifunctional molecules for treatment of immune disorders

The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.

Antibodies to TIGIT

The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.

Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies

The invention provides bispecific antibodies having one arm binding to a cancer associated antigen on a cancer cell, such as CD33, EGFR or PD-L1, and a second arm binding to a costimulatory molecule, such as OX40, CD40, GITR, ICOS or 4-1BB. Bridging by the bispecific antibody between cancer cells expressing the cancer associated antigen and immune cells expressing the costimulatory molecule results in clustering of the costimulatory molecules and selective activation of the immune cells at a location proximate to the cancer cells. Thus, the immune cells can exert an immunotherapeutic effect against the cancer cells with reduced toxicity to healthy tissue.

Bispecific antibodies which bind PD-L1 and GITR

Provided herein are humanized antibodies specific for CLL-1.

Humanized anti-CLL-1 antibodies

Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-OX40 antibodies and methods of using the same

The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.

Anti-human TROP-2 antibody having an antitumor activity in vivo

The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C&#x3bc;3 and C&#x3bc;4 regions of a C&#x3bc; constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C&#x3bc; constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.

Hybrid constant regions

Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.

Humanized anti-IL-20 antibody and uses thereof

The invention provides constant regions incorporating a cysteine mutation and linked to a &#x3bc; tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and &#x3bc; tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.

Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Nucleic acid encoding anti-OX40 antibodies

Growing community of inventors

Palo Alto, CA, United States of America

Naoya Tsurushita